|
Overall clinical and biological parameters of 55 obese subjects and 15 lean controls |
||
| Phenotype |
Obese subjects |
Lean controls |
|
|
||
| n |
55 |
15 |
| Female/Male |
52/3 |
15/0 |
| Age (years) |
40.13 ± 11.67 |
34.2 ± 8.52 |
| BMI (kg/m2) |
44.07 ± 9.06* |
23.67 ± 1.51 |
| Glucose homeostasis |
||
| Glucose (mmol/l) |
5.56 ± 1.70 |
4.82 ± 1.01 |
| Insulin (μU/ml) |
13.51 ± 8.57 |
7.20 ± 3.49 |
| QUICKI |
0.33 ± 0.05 |
0.36 ± 0.04 |
| Type 2 diabetes |
||
| Glycemia > 7 mmol/l or treatment |
6 (11%) |
0 |
| Lipid homeostasis |
||
| Cholesterol (mmol/l) |
5.22 ± 1.04 |
4.36 ± 1.05 |
| HDL cholesterol (mmol/l) |
1.27 ± 0.34 |
1.43 ± 0.23 |
| Triglycerides (mmol/l) |
1.40 ± 0.62† |
0.45 ± 0.10 |
| Adipokines |
||
| Leptin (ng/ml) |
54.55 ± 19.92 |
11.24 ± 1.12 |
| Adiponectin (μg/ml) |
7.14 ± 2.87 |
- |
| Risk factors |
||
| HDL < 1.03 mmol/l (M), < 1.29 mmol/l (F) |
26 (47%)* |
1 (6%) |
| Hypertension ≥ 130/85 mmHg |
11 (20%) |
0 |
| Glucose ≥ 5.6 mmol/l |
17 (31%) |
1 (6%) |
| Triglycerides ≥ 1.7 mmol/l |
11 (20%) |
0 |
| Inflammatory factors |
||
| TNF-α (pg/ml) |
1.77 ± 0.62 |
- |
| IL6 (pg/ml) |
2.24 ± 1.17 |
- |
| hsCRP (mg/dl) |
8.62 ± 10.38 |
- |
| Orosomucoid (g/l) |
0.99 ± 0.18 |
- |
| Serum amyloid A (μg/ml) |
21.35 ± 22.39 |
- |
| Hepatic factors |
||
| Aspartate aminotransferase (IU/l) |
22.66 ± 6.87 |
- |
| Alanine aminotransferase (IU/l) |
35.72 ± 18.56 |
- |
| γGT (mg/dl) |
45.91 ± 46.43 |
- |
|
*Bilateral significance p value < 0.05 for the difference between the two groups. †Bilateral significance p value < 0.001 for the difference between the two groups. Hyphens indicate parameters that were not available for the lean controls group. F, female; HDL, high-density lipoproteins; M, male. | ||
Henegar et al. Genome Biology 2008 9:R14 doi:10.1186/gb-2008-9-1-r14 |
||